Exploration of Clinical Breakpoint of Danofloxacin for Glaesserella parasuis in Plasma and in PELF.
Ontology highlight
ABSTRACT: Background: In order to establish the clinical breakpoint (CBP) of danofloxacin against G. parasuis, three cutoff values, including epidemiological cutoff value (ECV), pharmacokinetic-pharmacodynamic (PK-PD) cutoff value (COPD) and clinical cutoff value (COCL), were obtained in the present study. Methods: The ECV was calculated using ECOFFinder base on the MIC distribution of danfloxacin against 347 G. parasuis collected from disease pigs. The COPD was established based on in vivo and ex vivo PK-PD modeling of danofloxacin both in plasma and pulmonary epithelial lining fluid (PELF) using Hill formula and Monte Carlo analysis. The COCL was established based on the relationship between the possibility of cure (POC) and MIC in the clinical trials using the "WindoW" approach, nonlinear regress
SUBMITTER: Xu Z
PROVIDER: S-EPMC8300709 | biostudies-literature | 2021 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA